EA-2353 / endogena - LARVOL DELTA

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=14 | Terminated | Sponsor: Endogena Therapeutics, Inc | All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.

Trial completion date • Trial primary completion date • Trial termination • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

The promotion of visual function regeneration by intravitreal administration of EA-2353 in animal models of photoreceptor degeneration (ARVO 2024) - "EA-2353 treatment led to the significant regeneration of previously lost visual and retinal function (ERG responses, visual acuity, and contrast sensitivity) in a chemically induced animal model of retinal degeneration. Treatment with an EA-2353 analog (CompA) also led to a significant improvement in ERG responses in a genetic model of retinal degeneration."

Preclinical • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa (GlobeNewswire) - “Endogena Therapeutics Inc...announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP)....the ongoing trial is now in the expansion cohort stage. The trial (NCT05392751) is examining the safety, tolerability, and preliminary efficacy of intravitreal EA-2353...The trial has enrolled 14 patients with RP due to any pathologic genetic mutation and is being conducted across five US sites.The first patient started treatment in July 2022 and topline interim data is anticipated in early 2024.”

Enrollment status • P1/2 data • Ophthalmology • Retinitis Pigmentosa

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=14 | Active, not recruiting | Sponsor: Endogena Therapeutics, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=14 | Recruiting | Sponsor: Endogena Therapeutics, Inc | Trial completion date: Dec 2023 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Jun 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=14 | Recruiting | Sponsor: Endogena Therapeutics, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=14 | Not yet recruiting | Sponsor: Endogena Therapeutics, Inc

New P1/2 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa